4-fluoro-2-((2-methoxyethoxy)methyl)benzonitrile | 1569066-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-2-((2-methoxyethoxy)methyl)benzonitrile
• 英文别名: 4-Fluoro-2-((2-methoxyethoxy)methyl)benzonitrile；4-fluoro-2-(2-methoxyethoxymethyl)benzonitrile
• CAS: 1569066-21-2
• 化学式: C₁₁H₁₂FNO₂
• 分子量: 209.22
• InChiKey: TUSDERNLTZBUHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-fluoro-2-((2-methoxyethoxy)methyl)benzonitrile 在 sodium hydrosulfide hydrate 、 magnesium(II) chloride hexahydrate 、 四丁基溴化铵 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 6-(2-(4-fluoro-2-((2-methoxyethoxy)methyl)phenyl)thiazol-4-yl)benzo[d]oxazol-2(3H)-one
  参考文献：
  名称：

  Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines

  摘要：

  The metal-dependent phosphatase PPM1D (WIP1) is an important oncogene in cancer, with over-expression of the protein being associated with significantly worse clinical outcomes. In this communication we describe the discovery and optimization of novel 2,4-bisarylthiazoles that phenocopy the knockdown of PPM1D, without inhibiting its phosphatase activity. These compounds cause growth inhibition at nanomolar concentrations, induce apoptosis, activate p53 and display impressive cell-line selectivity. The results demonstrate the potential for targeting phenotypes in drug discovery when tackling challenging targets or unknown mechanisms. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2014.05.067
• 作为产物：
  描述：

  乙二醇甲醚 、 2-氰基-5-氟溴苄 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以84%的产率得到4-fluoro-2-((2-methoxyethoxy)methyl)benzonitrile
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES FONDUS ET UTILISATION DESDITS COMPOSÉS

  摘要：

  本发明提供了式(I)的化合物和其在治疗癌症中可接受的药用盐、水合物和溶剂结晶的用途。

  公开号：

  WO2014030001A1

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE
  申请人：The Institute of Cancer Research: Royal Cancer Hospital

  公开号：US20150232462A1

  公开（公告）日：2015-08-20

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof for use in the treatment of cancer:

  本发明提供式（I）的化合物及其药学上可接受的盐，水合物和溶剂化物，用于治疗癌症：
• US9550764B2
  申请人：——

  公开号：US9550764B2

  公开（公告）日：2017-01-24
• Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines
  作者：Matthew D. Cheeseman、Amir Faisal、Sydonia Rayter、Olivier R. Barbeau、Andrew Kalusa、Maura Westlake、Rosemary Burke、Michael Swan、Rob van Montfort、Spiros Linardopoulos、Keith Jones

  DOI：10.1016/j.bmcl.2014.05.067

  日期：2014.8

  The metal-dependent phosphatase PPM1D (WIP1) is an important oncogene in cancer, with over-expression of the protein being associated with significantly worse clinical outcomes. In this communication we describe the discovery and optimization of novel 2,4-bisarylthiazoles that phenocopy the knockdown of PPM1D, without inhibiting its phosphatase activity. These compounds cause growth inhibition at nanomolar concentrations, induce apoptosis, activate p53 and display impressive cell-line selectivity. The results demonstrate the potential for targeting phenotypes in drug discovery when tackling challenging targets or unknown mechanisms. (C) 2014 Published by Elsevier Ltd.
• [EN] FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FONDUS ET UTILISATION DESDITS COMPOSÉS
  申请人：CANCER RES INST ROYAL

  公开号：WO2014030001A1

  公开（公告）日：2014-02-27

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof for use in the treatment of cancer:

  本发明提供了式(I)的化合物和其在治疗癌症中可接受的药用盐、水合物和溶剂结晶的用途。